A purine derivative which inhibits cyclin-dependent kinases and induces G1 arrest.
ChEBI: Olomoucine is a 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor. It has a role as an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor. It is a member of 2,6-diaminopurines and a member of ethanolamines.
Cyclin-dependent kinase inhibitor that competes for the ATP binding site of the kinase. Selectively inhibits cdc2/cyclin B (IC 50 = 7 μ M), cdk2/cyclin A (IC 50 = 7 μ M), cdk2/cyclin E (IC 50 = 7 μ M), cdk/p35 kinase (IC 50 = 3 μ M) and ERK1/MAP kinase (IC 50 = 25 μ M). Arrests human fibroblasts in the G1 phase.
Olomoucine is a purine derivative which inhibits cyclin-dependent kinases and induces G arrest.
This ATP site-competitive purine derivative (FW = 298.35 g/mol; CAS 101622-51-9), systematically named 6-benzylamino-2-[2-hydroxyethylamino]- 9-methylpurine, is a potent inhibitor of cyclin-dependent kinases, with an IC50 value of 7 μM for both cdk1 and cdk2 and an IC50 value of 3 μM for cdk5, arresting cells in G1. Olomoucine also inhibits cytokinin 7b-glucosyltransferase.
[1]. vesel j, havlicek l, strnad m, et al. inhibition of cyclin-dependent kinases by purine analogues. eur j biochem. 1994 sep 1;224(2):771-86.
[2]. abraham rt, acquarone m, andersen a, et al. cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. biol cell. 1995;83(2-3):105-20.
[3]. tian ds, xie mj, yu zy, et al. cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. brain res. 2007 mar 2;1135(1):177-85.
